Celsee Diagnostics

About:

Celsee Diagnostics is an innovator of cutting-edge products in the emerging liquid-biopsy field.

Website: https://www.celsee.com

Twitter/X: celseedx

Top Investors: Ann Arbor SPARK, Jeffrey Schox, CKM Capital Partners

Description:

Celsee Diagnostics (formerly DeNovo Sciences) mission is to provide an easy to use platform for cancer research and diagnosis. Specifically, the company will sell an instrument system and reagent kit that allows for the separation, detection, and retrieval of circulating tumor cells (CTCs) from peripheral whole blood as an alternative to traditionally painful and invasive biopsies. Their company is developing a proprietary product that will not only allow researchers to identify and capture rare and difficult to harvest cancer cells in a microfluidic chip but also enable them to conduct downstream molecular analysis. This technology allows for the development of personalized therapies as well as the ability to monitor patient prognosis.

Total Funding Amount:

$12.8M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Plymouth, Michigan, United States

Founded Date:

2010-01-01

Contact Email:

info(AT)denovosciences.com

Founders:

Christopher Siemer, Priya Gogoi, Saedeh Sepehri

Number of Employees:

11-50

Last Funding Date:

2018-05-31

IPO Status:

Private

Industries:

© 2025 bioDAO.ai